The Effect of Synthesized Triazole and Ciprofloxacin Conjugated Peptide Compounds on Biological systems Biological effects of Triazole and Ciprofloxacin Conjugated Peptide.
Iranian Journal of Pharmaceutical Sciences,
Vol. 18 No. 2 (2022),
1 April 2022
,
Page 148-159
https://doi.org/10.22037/ijps.v18.42142
Abstract
Breast cancer is the most common cancer among women and only second in terms of cancer-related death in women. Finding new approaches to treat such cancers is critically important anti-cancer peptides (ACPs) offer the possibility of efficient-cancer drugs, and therefore, the development of drug delivery systems using ACPs as a synergism factor is an attractive strategy to address the current drawbacks of cancer therapeutics. This work investigated the cytotoxicity for a series of synthesized compounds based on triazole or ciprofloxacin conjugated peptides against T-47D breast cancerous cells and possible antibacterial effects. Wang resin was used for constructing peptide sequences on a solid support using the method of solid-phase peptide synthesis (spps) with the Fmoc strategy. Cytotoxicity of the synthesized peptide compounds was evaluated by MTT assay. The antimicrobial effect of synthesized peptide compounds was evaluated by agar well diffusion and Broth microdilution method. Most of the peptide compounds showed a cytotoxic effect toward T-47D cells. The antimicrobial effect of the peptide compounds was examined by agar well diffusion test and broth microdilution method. E. coli and S. aureus strains have shown the least amount of resistance. In the end, we suggest a new design based on these compounds and modifications to gain better anti-cancer agents
- Breast cancer, T-47D, Conjugated peptide anti-cancer drug, Cell-penetrating peptide, Cytotoxicity.
How to Cite
References
[2] Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J.cancer. (2010) 127 (12): 2893-917.
[3] Schwartz RS. Paul Ehrlich's magic bullets. N.Engl.J.Med. (2004) 350 (11): 1079-80.
[4] Ma L, Wang C, He Z, Cheng B, Zheng L and Huang K. Peptide-drug conjugate: a novel drug design approach. Curr.med.chem. (2017) 24 (31): 3373-96.
[5] Gaspar D, Veiga AS and Castanho MA. From antimicrobial to anticancer peptides. A review. Front.Microbiol. (2013) 4: 294.
[6] Raucher D and Ryu JS. Cell-penetrating peptides: strategies for anticancer treatment. Trends mol.med. (2015) 21 (9): 560-70.
[7] Firer MA and Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J. Hematol. Oncol. (2012) 5 (1): 1-16.
[8] Duncan R. Polymer conjugates as anticancer nanomedicines. Nat.rev.cancer. (2006) 6 (9): 688-701.
[9] Xiao Y-F, Jie M-M, Li B-S, Hu C-J, et al. Peptide-based treatment: a promising cancer therapy. J.Immunol.Res. (2015) 2015.
[10] Brandenburg L-O, Merres J, Albrecht L-J, Varoga D and Pufe T. Antimicrobial peptides: multifunctional drugs for different applications. Polym.J. (2012) 4 (1): 539-60.
[11] Tai W, Shukla RS, Qin B, Li B and Cheng K. Development of a peptide–drug conjugate for prostate cancer therapy. Mol.Pharm. (2011) 8 (3): 901-12.
[12] O'Connor, S.; Szwej, E.; Nikodinovic-Runic, J.; O'Connor, A.; Byrne, A. T.; Devocelle, M.; O'Donovan, N.; Gallagher, W. M.; Babu, R.; Kenny, S. T.; Zinn, M.; Zulian, Q. R.; O'Connor, K. E., The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate. Biomater. Sci. 2013 34 (11): 2710-2718.
[13] Regberg J, Srimanee A and Langel U. Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. J.Pharm.. (2012) 5 (9): 991-1007.
[14] Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G and Prochiantz A. Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent*. J.Biol.Chem. (1996) 271 (30): 18188-93.
[15] Vivès E, Schmidt J and Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. (2008) 1786 (2): 126-38.
[16] Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H and Beck-Sickinger AG. Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem. (2001) 44 (9): 1341-8.
[17] Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G and Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A. (1997) 94 (2): 652-6.
[18] Dharap SS, Qiu B, Williams GC, Sinko P, Stein S and Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release. (2003) 91 (1-2): 61-73.
[19] Veronese FM, Schiavon O, Pasut G, Mendichi R, et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem. (2005) 16 (4): 775-84.
[20] Hu FQ, Liu LN, Du YZ and Yuan H. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomater. Sci.. (2009) 30 (36): 6955-63.
[21] Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM and Groot K. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. J.Cancer. (1999) 85 (12): 2608-15.
[22] Mazel M, Clair P, Rousselle C, Vidal P, et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs. (2001) 12 (2): 107-16.
[23] Liang JF and Yang VC. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett. (2005) 15 (22): 5071-5..
[24] Tu Y and Zhu L. Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate. J Control Release. (2015) 212: 94-102.
[25] Hannu K, Johanna M and Ulf-Håkan S. KLK-targeted Therapies for Prostate Cancer. Ejifcc. (2014) 25 (2): 207-18.
[26] Peyton LR, Gallagher S and Hashemzadeh M. Triazole antifungals: a review. Drugs Today (Barc). (2015) 51 (12): 705-18.
[27] da Silva Fde C, de Souza MC, Frugulhetti, II, Castro HC, et al. Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates. Eur J Med Chem. (2009) 44 (1): 373-83.
[28] Wang XL, Wan K and Zhou CH. Synthesis of novel sulfanilamide-derived 1,2,3-triazoles and their evaluation for antibacterial and antifungal activities. Eur J Med Chem. (2010) 45 (10): 4631-9.
[29] Kaushik, C. P.; Lal, K.; Kumar, A.; Kumar, S., Synthesis and biological evaluation of amino acid-linked 1,2,3-bistriazole conjugates as potential antimicrobial agents. Med.Chem.Res. 2014, 23 (6): 2995-3004.
[30] Lal K and Yadav P. Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents. Anticancer Agents Med Chem. (2018) 18 (1): 21-37.
[31] Bozorov K, Zhao J and Aisa HA. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview. Bioorg Med Chem. (2019) 27 (16): 3511-31.
[32] Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA and Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. (1988) 35 (4): 373-447.
[33] Sriram D, Yogeeswari P, Senchani G and Banerjee D. Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg Med Chem Lett. (2007) 17 (8): 2372-5.
[34] El-Azab AS, Abdel-Aziz AA, Ghabbour HA, Bua S, et al. Carbonic Anhydrase Inhibition Activities of Schiff's Bases Based on Quinazoline-Linked Benzenesulfonamide. Molecules. (2022) 27 (22).
[35] Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG and Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. (2002) 86 (3): 443-8.
[36] Hu YQ, Gao C, Zhang S, Xu L, et al. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur J Med Chem. (2017) 139: 22-47.
[37] Zhang GF, Liu X, Zhang S, Pan B and Liu ML. Ciprofloxacin derivatives and their antibacterial activities. Eur J Med Chem. (2018) 146: 599-612.
[38] T EK, Thongararm P, Roytrakul S, Meesuk L and Chumnanpuen P. Prediction of anticancer peptides against MCF-7 breast cancer cells from the peptidomes of Achatina fulica mucus fractions. Comput Struct Biotechnol J. (2016) 14: 49-57.
[39] Baharloui M, Mirshokraee SA, Monfared A and Houshdar Tehrani MH. Design and Synthesis of Novel Triazole-based Peptide Analogues as Anticancer Agents. Iran J Pharm Res. (2019) 18 (3): 1299-308.
[40] Esfandiari Mazandaran K, Mirshokraee SA, Didehban K and Houshdar Tehrani MH. Design, Synthesis and Biological Evaluation of Ciprofloxacin- Peptide Conjugates as Anticancer Agents. Iran J Pharm Res. (2019) 18 (4): 1823-30.
[41] Van Meerloo, Johan, Gertjan JL Kaspers, and Jacqueline Cloos. "Cell sensitivity assays: the MTT assay." Cancer cell culture: methods and protocols (2011): 237-245.
[42] Balouiri M, Sadiki M and Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. (2016) 6 (2): 71-9.
[43] Futaki S, Suzuki T, Ohashi W, Yagami T, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. (2001) 276 (8): 5836-40.
[44] Rollando, Rollando, and Kestrilia Rega Prilianti. "Sterculia Quadrifida R. Br ethyl acetate fraction increases cisplatin cytotoxicity on T47D breast cancer cells. Int. J. Pharm. Res. 10.03 (2018): 204-212.
[45] Bower, Molly A., et al. "Walking the fine line between intracellular and membrane activities of antibacterial peptides. Letters in Peptide Science 10 (2003): 463-473.
[46] Sadler K, Eom KD, Yang JL, Dimitrova Y and Tam JP. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochem. (2002) 41 (48): 14150-7..
[47] Cho WM, Joshi BP, Cho H and Lee KH. Design and synthesis of novel antibacterial peptide-resin conjugates. Bioorg Med Chem Lett. (2007) 17 (21): 5772-6.
[48] Rana N, Huang S, Patel P, Samuni U and Sabatino D. Synthesis, characterization and anti-cancer activity of a peptide nucleolipid bioconjugate. Bioorg Med Chem Lett. (2016) 26 (15): 3567-71.
[49] Karpiński, Tomasz M., and Anna K. Szkaradkiewicz. "Anti-cancer peptides from bacteria. Bangladesh J. Pharmacol.8.3 (2013): 343-348.
- Abstract Viewed: 72 times
- IJPS-Vol18- Issue 2-page 148-159 Downloaded: 38 times